{
    "root": "8112f04f-cd6e-4858-a1a4-060bfde2066f",
    "code": "34391-3",
    "codeSystem": "2.16.840.1.113883.6.1",
    "displayName": "HUMAN PRESCRIPTION DRUG LABEL",
    "name": "Tizanidne hydrochloride",
    "value": "20240307",
    "ingredients": [
        {
            "name": "TIZANIDINE HYDROCHLORIDE",
            "code": "B53E3NMY5C"
        },
        {
            "name": "CORN SYRUP",
            "code": "9G5L16BK6N"
        },
        {
            "name": "STARCH, CORN",
            "code": "O8232NY3SJ"
        },
        {
            "name": "SUCROSE",
            "code": "C151H8M554"
        },
        {
            "name": "HYPROMELLOSE 2910 (3 MPA.S)",
            "code": "0VUT3PMY82"
        },
        {
            "name": "SILICON DIOXIDE",
            "code": "ETJ7Z6XBU4"
        },
        {
            "name": "FD&C BLUE NO. 1",
            "code": "H3R47K3TBD"
        },
        {
            "name": "FD&C RED NO. 3",
            "code": "PN2ZH5LOQY"
        },
        {
            "name": "TITANIUM DIOXIDE",
            "code": "15FIX9V2JP"
        },
        {
            "name": "GELATIN, UNSPECIFIED",
            "code": "2G86QN327L"
        },
        {
            "name": "SHELLAC",
            "code": "46N107B71O"
        },
        {
            "name": "PROPYLENE GLYCOL",
            "code": "6DC9Q167V3"
        },
        {
            "name": "POTASSIUM HYDROXIDE",
            "code": "WZH3C48M4T"
        }
    ],
    "indications": "Tizanidine hydrochloride is indicated for the management of spasticity. Because of the short duration of therapeutic effect, treatment with tizanidine hydrochloride should be reserved for those daily activities and times when relief of spasticity is most important [see Dosage and Administration (2.1)].",
    "contraindications": "Recommended starting dose: 2 mg; dose can be repeated at 6- to 8-hour intervals, up to a maximum of 3 doses in 24 hours ( 2.1 ) Dosage can be increased by 2 mg to 4 mg per dose, with 1 to 4 days between increases; total daily dose should not exceed 36 mg ( 2.1 ) Tizanidine pharmacokinetics differs between tablets and capsules, and when taken with or without food. These differences could result in a change in tolerability and control of symptoms ( 2.1 , 12.3 ) To discontinue tizanidine hydrochloride capsules, decrease dose slowly to minimize the risk of withdrawal and rebound hypertension, tachycardia, and hypertonia ( 2.2 )",
    "warningsAndPrecautions": "16.1 Tizanidine hydrochloride capsules\n                  \n                  Tizanidine capsules 2 mg have a hard gelatin size \"3\" light blue opaque capsule, imprinted \"2MG\" with white ink on cap and \"Tiza\" & \"circle of thin line\" with white ink on body, containing light yellow to yellow color pellets.\n                  NDC: 72162-1860-2: 150 Capsules in a BOTTLE\n                  Store at 25째C (77째F); excursions permitted to 15 to 30째C (59 to 86째F) [see USP Controlled Room Temperature]. Dispense in containers with child resistant closure.\n                  Repackaged/Relabeled by:\n                  Bryant Ranch Prepack, Inc.\n                  Burbank, CA 91504",
    "adverseReactions": "Tizanidine hydrochloride capsules is contraindicated in patients taking potent inhibitors of CYP1A2, such as fluvoxamine or ciprofloxacin [see Drug Interactions (7.1, 7.2)]."
}